linjc16/ctgov huggingface dataset:
Urinary Transglutaminase 2 as a Biomarker for Kidney Allograft Fibrosis

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to verify the ability of transglutaminase type 2 to predict rejection or chronic allograft nephropathy of renal allograft. On the basis of biomolecular mechanisms aggravating chronic allograft nephropathy, we eventually expect to develop the remedy to prevent chronic allograft nephropathy after kidney transplantation.

Official Title
-----------------
Development of a Diagnostic Kit for Urinary Transglutaminase 2 as a Biomarker for Kidney Allograft Fibrosis

Conditions
-----------------
Kidney Allograft Fibrosis, Kidney Transplant Failure and Rejection

Intervention / Treatment
-----------------
* Diagnostic Test: observational(urinary biomarker for kidney allograft fibrosis)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: kidney transplant recipients from cadaveric or living donors kidney transplant recipients who take immunosuppressants regularly kidney transplant recipients who voluntarily agree to participate in this trial Exclusion Criteria: multiorgan transplant recipients kidney transplant recipients with active infection kidney transplant recipients with alcohol or drug addiction

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: observational(urinary biomarker for kidney allograft fibrosis)|After an informed consent is obtained, urine specimens will be collected prospectively before kidney transplantation (if available) and 3rd and 7th day, 1st, 3rd, and 6th month post-transplant. About 35 50ml of urine sample is collected from each patient. For each urine specimen, 0.5 ml of a protease inhibitor mixture (5mM 4-(2-animoethyl) benzensulfonyl fluoride hydrolchloride, 2 μM Leupeptin-hemisulfate, and 3.3 mM Sodium azide) is added. To remove urinary sediments including whole cells, large membrane particles, and other debris, urine specimens are centrifuged at a rate of 4000 rpm for 15 minutes at 4 ℃. An aliquot of supernatant is stored at -80 ℃ until use. Urinary biomarkers including transglutaminase 2 are quantified using ELISA or CBA. In addition, urinary exosomes are isolated and analyzed. When a for-cause biopsy is done for some patients, the correlation between biomarkers and pathologic diagnosis will be assessed.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change of level of urinary transglutaminase 2 |  | 3 days, 7 days, 1 month, 3 months, 6 months post-transplant | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
transglutaminase type 2, kidney transplantation, chronic allograft nephropathy, biomarker
Iron and Vitamin Supplementation in Hip/Knee Surgery

Study Overview
=================
Brief Summary
-----------------
Randomized controlled trial to evaluate the efficacy of oral iron supplementation plus cofactors in reducing the prevalence of preoperative anemia in a cohort of 60 patients undergoing elective prosthetic hip or knee surgery.

Official Title
-----------------
Emacrit Plus in Prosthetic Hip and Knee Surgery

Conditions
-----------------
Orthopedic Disorder, Hip Arthropathy, Knee Arthropathy, Anemia, Iron Poor Blood

Intervention / Treatment
-----------------
* Dietary Supplement: Iron plus folic acid, vitamin B2, B6, B12, C, and E


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males and females ASA 1, 2, or 3 No neuropsychiatric conditions Acceptance of informed consent Elective prosthetic hip or knee surgery Exclusion Criteria: ASA 4 Present or past neuropsychiatric conditions Hip or knee revision surgery Use of iron as dietary supplement Known erythrocytosis Incompatible hypersensitivities Iron metabolism disorders Lymphoproliferative disorders

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention (group A)<br>Patients who are subjected to the intervention, being iron plus other cofactors for hematopoiesis, other than the standard of care. | Dietary Supplement: Iron plus folic acid, vitamin B2, B6, B12, C, and E<br>* A number of 30 subjects are supplemented with iron plus folic acid, vitamin B2, B6, B12, C, and E daily for 60+/-15 days before orthopedic surgery.<br>|
| No Intervention: Control (group B)<br>Patients who are not subjected to the intervention and follow the standard of care. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of blood hemoglobin levels | Change of hemoglobin concentration (g/dl) from baseline and after 60 days +/- 15 days | Baseline and 60 days +/- 15 days |
Pedialyte or Gatorade for Viral Gastroenteritis in Adults: a Randomized, Controlled Trial

Study Overview
=================
Brief Summary
-----------------
Background: Pedialyte and Gatorade are advocated for the treatment of dehydration in viral gastroenteritis, but there is limited evidence to support their use. Objective: To examine the efficacy, safety and palatability of Pedialyte, Gatorade, and a New Oral Rehydration Solution (NS). Design: Randomized double blind. Setting: Inpatient, community hospital. Patients/Interventions: 75 consecutive adult patients (m/f=44/33) admitted with viral gastroenteritis were randomized to receive Gatorade, Pedialyte or NS for 48 hours. A yogurt/rice diet was allowed ad libitum. Measurements: Stool and urine output, electrolytes, fluid intake, body weight, hematocrit and palatability of solutions. Limitations: Smaller sample size and higher drop out (20%).

Conditions
-----------------
Gastroenteritis

Intervention / Treatment
-----------------
* Drug: Gatorade, Pedialyte and New Solution


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects were included if they had mild-to-moderate diarrhea, with mildly sunken eyes and a clinical assessment of dehydration of less than 5%, a serum sodium concentration between 130-150 mEq/L, adequate general health and nutrition, a BUN/creatinine ratio of >20 and with a normal pulse rate for age and degree of fever and adequate skin turgor Exclusion Criteria: Patients were excluded if they had hyperthermia (>39.0º C), serum sodium >150 mEq/L or <130 mEq/L, white cell count >15,000, bloody diarrhea (dysentery), abnormal cardiovascular or renal function or an underlying metabolic or nutritional disorder and most importantly, if the clinical assessment of dehydration was >7% that suggested a need for intravenous fluids.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Gatorade, Pedialyte and New Solution|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Early Reassessment of Intravenous Antiinfective Therapy Due to Antiinfective Reminders (AIR Study)

Study Overview
=================
Brief Summary
-----------------
Switching from intravenous application of antiinfective agents to oral therapy is often performed late including high costs and risk of complications. This study will investigate the impact of displayed reminders in the electronic patient chart after 60h of intravenous therapy with an antiinfective agent.

Detailed Description
-----------------
Switching from intravenous application of antiinfective agents to oral therapy is often performed late including high costs, risk of complications as well as higher workload on nursing. This study will investigate the impact of displayed reminders in the electronic patient chart after 60h of intravenous therapy with an antiinfective agent.

Official Title
-----------------
Early Reassessment of Intravenous Antiinfective Therapy Due to Antiinfective Reminders (AIR Study)

Conditions
-----------------
Infection as Complication of Medical Care

Intervention / Treatment
-----------------
* Other: electronic reminders


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: all in-patients in treatment with an intravenous antiinfective for >60h, hospitalized in a ward with computerized physician order entry (cpoe) Exclusion criteria: outpatients, ward without cpoe, no intravenous antiinfective treatment
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: electronic reminders<br>Behavioral: Early switching from intravenous to oral antiinfective agents due to electronic reminders | Other: electronic reminders<br>* Behavioral: Early switching from intravenous to oral antiinfective agents due to electronic reminders<br>* Other names: computerized decision support;|
| No Intervention: no electronic reminders<br>Behavioral: Early switching from intravenous to oral antiinfective agents without computerized decision support | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| duration of intravenous antiinfective therapy until switching |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| costs (per year, per day and patient) |  | 1 year | 
| defined daily doses (per 100 days) |  | 1 year | 
| duration of hospitalization |  | 1 year | 
| ratio of narrow to broad-spectrum antibiotics |  | 1 year | 
| requests for consultations |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Early reassessment of intravenous antiinfective therapy
Microbiological Characterization and Nasal Carriage Rates of Methicillin Resistant Staphylococcus Aureus (MRSA) in Vancouver Downtown Eastside

Study Overview
=================
Brief Summary
-----------------
We plan to compare data from 300 nasal swab in Vancouver's Downtown Eastside taken in 2001 to data obtained in 2005. The nasal carriage rate of MRSA and the specific characteristic of each MRSA found will be analyzed. A limited amount of associated information will be obtained

Detailed Description
-----------------
MRSA samples will be characterized by pulse field gel electropheresis. An 9 item questionnaire will be administered.

Official Title
-----------------
The Prevalence of Panton Valentine Leukocidin, Exfoliative Toxin and Agr Genotypes in Staphylococcus Aureus Nasal Colonization in Vancouver's Eastside Community

Conditions
-----------------
Nasal Colonization With MRSA Bacteria

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient had a microbiological sample submitted from the emergency department of the study hospital from 2001- 2005 which grew MRSA. Exclusion Criteria:
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MRSA, USA300, CMRSA-10, CMRSA-6, soft tissue abscesses
Role of Intima-media Thickness in Determining Arteriogenic Erectile Dysfunction

Study Overview
=================
Brief Summary
-----------------
Erectile dysfunction.

Detailed Description
-----------------
The intima media thickness is increasingly used as a surrogate end point of vascular outcomes in clinical trials aimed at determining the success of interventions that lower risk factors for atherosclerosis and associated diseases (stroke, myocardial infarction and peripheral artery diseases, like disease of cavernosal artery). The investigators hypothesized that the IMT of cavernosal artery would add to the predictive value of vasculogenic erectile dysfunction risk and outcomes. This study seeks to evaluate these hypotheses with our experience, investigating the predictive accuracy of Cavernosal Doppler ultrasound findings for discriminating patients with vasculogenic erectile dysfunction.

Official Title
-----------------
Predictive Value of Measuring Intima-media Thickness of Cavernosal Artery in Diagnosis of Arteriogenic Erectile Dysfunction by Penile Duplex

Conditions
-----------------
Erectile Dysfunction

Intervention / Treatment
-----------------
* Device: Penile Duplex


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Erectile dysfunction patients Exclusion Criteria: Penile trauma.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Penile Duplex<br>Measuring intima media thickness | Device: Penile Duplex<br>* Measuring intima media thickness<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| erectile dysfunction | intima media thickness | six months |
Sonosalpingography After Hysteroscopic Tubal Occlusion

Study Overview
=================
Brief Summary
-----------------
Sonosalpingography is done to assess the efficacy of hysteroscopic tubal occlusion by roller ball electrode.

Official Title
-----------------
Sonosalpingography in Assessment of Efficacy of Hysteroscopic Tubal Occlusion by Roller Ball Electrode

Conditions
-----------------
Fallopian Tube Occlusion

Intervention / Treatment
-----------------
* Other: sonosalpingography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Infertile patients with hydrosalpinges requiring in vitro fertilization irreversible contraception Exclusion Criteria: Acute pelvic inflammatory disease

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients receiving hysteroscopic tubal occlusion<br>This group will have sonosalpingography done for them one month after the tubal occlusion. | Other: sonosalpingography<br>* transvaginal ultrasound with saline infusion<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The presence of fluid in douglas pouch detected by transvaginal ultrasound after saline infusion through the cervix | after saline infusion is done, presence of fluid in douglas pouch means that hysteroscopic occlusion of tubes was not successful. | immediate |
Diagnosis and Survival Prediction of Pancreatic Cancer by Machine Learning of Image Data

Study Overview
=================
Brief Summary
-----------------
This prospective cohort study is designed to investigate the diagnostic ability and prediction accuracy of pancreatic cancer by radiomics data and clinical data.

Detailed Description
-----------------
In this study, investigators aimed to investigate the diagnostic performance and prediction accuracy of pancreatic cancer by radiomics data and clinical data, which include CT scan, MRI, PET-CT, PET-MR, ultrasound, and clinical data.

Official Title
-----------------
Diagnosis and Survival Prediction of Pancreatic Cancer by Machine Learning of Image Data

Conditions
-----------------
Pancreatic Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of pancreatic tumor; Must have CT / MRI / ultrasound data and pathology diagnosis Exclusion Criteria: Have other tumors along with pancreatic tumor; Clinical information missing

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient overall survival | Patient overall survival, from the time of diagnosis of pancreatic tumor to the death of the patient. | up to 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pathology diagnosis | Pathology diagnosis of the patient, such as adenocarcinoma, pancreatic neuroendocrine tumors, intraductal Papillary Mucinous Neoplasm, et al. | intraoperative | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pancreatic Cancer, Machine Learning, Radiomics, CT, MRI, Ultrasound
The Safety and Efficacy of Albis®: The Prevention of Aspirin-induced Gastrointestinal Ulcers in Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to research the safety and efficacy of Albis® for the prevention of aspirin-induced gastrointestinal ulcers in patients taking low-dose aspirin.

Detailed Description
-----------------
The Safety and Efficacy of Albis®: The Prevention of Aspirin-induced Gastrointestinal Ulcers in Patients taking Low-dose Aspirin, A pilot study Double-Blind, Placebo-Controlled, Randomized, Multicenter, Parallel, Prospective study

Official Title
-----------------
The Safety and Efficacy of Albis®: The Prevention of Aspirin-induced Gastrointestinal Ulcers in Patients Taking Low-dose Aspirin, A Pilot Study

Conditions
-----------------
Patients Taking Low-dose Aspirin

Intervention / Treatment
-----------------
* Drug: Albis Tab
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female, aged 20 to 80 years Subjects identified with at least one of the following diagnosis (Angina, Myocardial Infarction(Old), Cerebrovascular Disease, Peripheral Vascular Disease, Diabetes, Hypertension, Hypercholeseterolemia, Obesity) who are required to take a low dose of Aspirin (100mg/day) for more than 12 weeks. Exclusion Criteria: Females who are pregnant, nursing, or planning a pregnancy during the study period or females of childbearing potential Peptic ulcer or Reflux oesophagitis hemostatic disorder or coagulation disorder Known allergy or hypersensitivity to the study medication

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Albis<br>Drug: Albis Tab 2 tab, twice a day | Drug: Albis Tab<br>* 2 Tab, twice a day, 12 weeks<br>|
| Placebo Comparator: Placebo<br>Placebo 2 tab, twice a day | Drug: Placebo<br>* 2 Tab, twice a day, 12 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence rate of Gastric Ulcer |  | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence rate of gastiritis |  | 2 years |
Fast Food Photo Study 2

Study Overview
=================
Brief Summary
-----------------
Participants will be exposed to a hypothetical fast food menu, asked to place a hypothetical lunch order, and will then be exposed to a second menu with several changes made to the menu. Participants will be asked to identify as many changes as possible on this second menu, and then complete a survey about their eating tendencies and demographics.

Detailed Description
-----------------
The menu with changes will feature changes to both calories and prices, allowing for measures of whether participants notice such changes and the order in which changes are noticed.

Official Title
-----------------
Detecting Changes on Fast Food Menu

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Other: Changed menu


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 or older, agrees to consent form Exclusion Criteria: N/A

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Changed menu<br>All participants will be exposed to the same changed menu after making their hypothetical choice. Changes will include reduced calorie labels, reduced prices, and changes to item descriptions. | Other: Changed menu<br>* After making the hypothetical choice, participants will be exposed to a menu with changed calorie and price labels, as well as several other changes.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants who notice calorie change |  | Participants will have 2 minutes to notice changes on the menu | 
| Number of participants who notice price change |  | Participants will have 2 minutes to notice changes on the menu | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Within-participant ranking of the order in which changes were noticed |  | Participants will have 2 minutes to notice changes on the menu | 
| Total number of changes noticed |  | Participants will have 2 minutes to notice changes on the menu | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fast food literacy